Inqovi
Generic name: Cedazuridine And Decitabine
Drug class:
Antineoplastic combinations
Usage of Inqovi
Inqovi contains a combination of Cedazuridine and decitabine.
Inqovi is a prescription medicine that is used to treat treat adults with myelodysplastic syndromes (MDS, including chronic myelomonocytic leukemia (CMML). Myelodysplastic syndromes are types of blood or bone marrow disorders.
It is not known if Inqovi is safe or effective in children..
Inqovi side effects
Get emergency medical help if you have signs of an allergic reaction to Inqovi: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
Your treatments may be delayed or permanently discontinued if you have certain side effects.
Common Inqovi side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Inqovi
To make sure Inqovi is safe for you, tell your doctor if you have ever had::
You may need to have a negative pregnancy test before starting this treatment.
Cedazuridine and decitabine can harm an unborn baby or cause birth defects if the mother or the father is using this medicine.
Inqovi may affect fertility (ability to have children) in men. However, it is important to use birth control to prevent pregnancy because the medicine can harm an unborn baby.
You should not breastfeed while using Inqovi and for at least 2 weeks after your last dose.
Inqovi is not approved for use by anyone younger than 18 years old.
Relate drugs
- Akeega
- Cytarabine and daunorubicin liposomal
- Cedazuridine and decitabine
- Daunorubicin and cytarabine liposome
- Decitabine and cedazuridine
- Inqovi
- Kisqali Femara Co-Pack
- Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
- Letrozole and ribociclib
- Lonsurf
- Niraparib and abiraterone
- Nivolumab and relatlimab
- Nivolumab/relatlimab-rmbw
- Opdualag
- Ribociclib and letrozole
- Tipiracil and trifluridine
- Trifluridine and tipiracil
- Vyxeos
- Vyxeos liposomal
How to use Inqovi
Usual Adult Dose for Myelodysplastic Syndrome:
1 tablet (containing 100 mg cedazuridine and 35 mg decitabine) orally once daily on Days 1 through 5 of each 28-day cycle for a minimum of 4 cycles until disease progression or unacceptable toxicity; a complete or partial response may take longer than 4 cycles Comments: -Consider administering antiemetics prior to each dose to minimize nausea and vomiting. Use: For myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
Warnings
Inqovi affects your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, chills, cough, mouth sores, or unusual bleeding or bruising.
Do not give Inqovi to other people, even if they have the same symptoms that you have. It may harm them.
What other drugs will affect Inqovi
Other drugs may interact with cedazuridine and decitabine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions